Leadership in Biotech

Tag: finance

A first look at income statements: revenue, costs and profits

Today we talk about the income statement, possibly the most discussed financial statement.

The income statement attempts to measure whether the products or services that a company provides are profitable when everything gets added up. In other words, how many sales did a company make during a period of time, how much did it cost to make those sales, and what profit is left over.

The income statement can help answer the following questions about a company’s financial health:

  • How much is revenue growing?
  • What is the gross profit margin for sales?
  • What percentage of revenue results in net profit after all expenses?
  • How much does the business repay shareholders versus reinvesting (and what that might mean for how the company sees its future)?

As a quick aside, there’s a fundamental accounting rule called ‘The Matching Principle’ at play in the income statement that is worth mentioning here. Briefly, the matching principle seeks to match the cost with its associated revenue to determine profits in a given time period. This principle will come up throughout the sections about the income statement.

There are always 3 main categories on an income statements:

  • Sales or revenue is at the top (fun fact: when fancy people say ‘top-line growth’ they mean sales growth, because sales is always at the top of the income statement)
  • Costs and expenses are in the middle
  • Profit is at the bottom

Today, we will focus on just identifying how to read these statements.

Parsing the Income Statement

To do that, let’s go back to Bio-Techne and take a look at their annual income statement for 2022 by pulling up the most recent 10-K filing again.

First thing to notice is that it doesn’t say ‘Income Statement.’ Instead, it has this:

Report text: Item 8. Financial Statements and Supplementary Data. Consolidated Statements of Earnings and Comprehensive Income

It can also be called the ‘profit and loss statement’ or ‘P&L statement’ or ‘operating statement’ or ‘statement of operations’ or ‘statement of earnings’ or ‘earnings statement’ or some combination therein, like we have here for our example. Sometimes it feels like those crafty finance people intentionally obfuscate things. 😉

The other things to notice here are that

  • we are looking at the income statement for the Bio-Techne Corporation and Subsidiaries, i.e., the whole company, not one division, and
  • numbers are listed in thousands- sometimes this can be millions, so best to pay attention.

So here it is for Bio-Techne. The Income Statement. Remember, sales or revenue is at the top, costs and expenses are in the middle, profit is at the bottom. We’ll take these each separately in the upcoming posts.

Screenshot of Bio-Techne Income Statement

A note on footnotes

Before we wrap up today, I want to draw your attention to the ‘See Notes to Consolidated Financial Statements’ at the bottom of the Income Statement.

These footnotes are required per the rules of accounting to explain how the totals were arrived at. Remember that the rules of accounting are meant to be applied consistently, so that one can readily compare trends over time. However, it can be perfectly legitimate to modify the approach, and that modification will be called out in the footnotes. So, every now and again there are very interesting nuggets in the footnotes, however, there are usually quite a lot of them.

Here’s an example footnote about inventory basically explaining that they make more than the sales demand due to ‘economies of scale through a highly controlled manufacturing process.’ Those of you who have worked in regulated manufacturing environments on these types of products will know that manufacturing runs or batch sizes are validated at particular amounts/volumes- you can’t just manufacture to whatever volume you want, and that impacts the financial statements:

Screenshot of a footnote concerning inventories from a Bio-Techne Income Statement

That covers the basics. In the next post, we’ll talk about revenue! As always, you can sign up to the mailing list to be updated when the next installment is out.

Stylized illustration of a scientist examining an income statement, a balance sheet, and a cash flow statement

Every scientist’s dream: Understanding financial statements

Every company that trades on the stock market has to share their financial results every three months, i.e., quarterly. Once a year, they produce an annual report, which is basically a blown out version of these quarterly documents.. You know those “10-K (annual reports) and 10-Q (quarterly reports)” we found for Bio-Techne on EDGAR? That’s what I’m talking about. 🙂

There’s quite a bit you can learn from these documents, but here we will focus on the financial statements.

The main statements are

  • the income statement,
  • the balance sheet, and
  • the cash flow statement.

These statements are not just for life sciences companies. All companies that trade on the stock market are required to file these documents. Nonprofit organizations and government agencies use similar statements, although there are a few key differences we won’t cover here.

The income statement shows us how much money the company makes. This statement matches the expenses with the revenue, so one can see how efficient the company is at making money.

The balance sheet shows us what the company has (i.e. its assets) and what it owes (i.e. its liabilities). The difference between assets and liabilities is equity, the part that belongs to the owners/shareholders of the company.

The cash flow statement simply tracks how much money is coming in and going out of the business over a period of time. As soon as money moves in or out, the cash flow result is recorded.

Putting together the full picture

These three statements together give us a clear picture of how well the company is doing financially. Of course, there’s considerable nuance in how a company approaches these statements that can impact how well or poorly it looks like it’s doing. There are rules governing accounting and finance, but there’s also quite a bit of art to it, and when companies get too creative or allow significant bias to creep in based on market pressure, that’s where you start to head towards fraud and financial ruin. We’ll cover that along the way, too.

One way to think about accounting is similar to the way you would run a scientific experiment – In an experiment you have controls – to measure the result vs a comparison point.  One of the most fundamental accounting rules for GAAP (Generally Accepted Accounting Principles) is that GAAP is consistently applied- so you have a control in place and can do valid comparisons between quarters, years and months, just like a good trial or experiment.

These financial statements are the gold mine of information that stock analysts use to figure out how much these companies are worth, and what their stock price should be.

While stock analysts also look at other data outside of these basic financial statements, even if you only had the data in these statements, you’d have a strong understanding of the company’s past performance and current state. And from there, with some insight into the market that the company operates in, you can start to make some predictions about the future.

In the next part, we’ll explore the income statement. We’ll go through the structure of it, then we’ll look at some real world examples.

Stay tuned! (Which is easier if you join my mailing list to be updated when the next installment comes out.)

Stylized illustration of a scientist looking through financial documents and reports

How to learn the financial basics about a new (to you) business

Before we start exploring financial statements, let’s start with the basics on where to find information about a life sciences company with which we’re unfamiliar.

Let’s take the example of Bio-Techne Corporation.

Maybe you’re already familiar with Bio-Techne Corporation. Maybe not. Either way I bet you will learn something from digging through their financial statements.

Our first step is to go to the Electronic Data Gathering, Analysis and Retrieval (EDGAR) tool from the US Securities and Exchange Commission (SEC):

https://www.sec.gov/edgar/searchedgar/companysearch

You can type “Bio-Techne” in the “Company and Person Lookup” field. As you type, automatic suggestions will be displayed below the search field. Once you see Bio-Techne, click that suggestion. If you simply click the gray “search” button on the right, you will be taken to a much broader page of search results instead of the page specifically for Bio-Techne.

Alternatively, you can search Google for “Bio-Techne stock”, find that its stock ticker is “TECH”, and put “TECH” in the “Company and Person Lookup” field instead.

On the right, you’ll see “10-K (annual reports) and 10-Q (quarterly reports)”, click the “+” sign, then open the most recent 10-K, which was filed on August 24, 2022.

Screenshot of the EDGAR listing for Bio-Techne, with the 10-K and 10-Q section highlighted

Look for the 10-K and 10-Q section on the right

10-K Overview

You’ll see a table of contents, where you can click on “Item 1. Business”. The very first section there is titled “Overview”

Here’s a summarized version of what we find

  • Bio-Techne Corporation is a global life sciences company that provides products and services for research and clinical diagnostics.
  • The company operates in two segments: Protein Sciences and Diagnostics & Genomics.
  • The Protein Sciences segment offers proteins, antibodies, immunoassays, cell and gene therapy solutions, and instruments for biotechnology and pharmaceutical customers.
  • The Diagnostics and Genomics segment offers molecular diagnostic products, cytogenetics media, and clinical controls for clinical laboratories and hospitals.

Fantastic!

Even after this little bit of reading, we have a good sense of what Bio-Techne Corporation does. It’s a products and services company in protein sciences and diagnostics/genomics. In other words, they provide reagents and instrumentation to researchers for both research and diagnostic test development and deployment.

Business Risk Factors

Now let’s move to “Item 1A. Risk Factors”.

This is where management lists the risks to business success.

Even beyond risk management, it gives us a good understanding of how the business runs.

For example, Bio-Techne lists 6 fairly generic categories of risk, with each section having more detailed risks listed:

  1. Economic and Industry Risks
  2. Acquisition and Investment Risks
  3. Strategic and Operational Risks
  4. Intellectual Property Risks
  5. Financial and Tax Risks
  6. Legal, Regulatory, Compliance and Reputational Risks

These are my learnings from the risk factors (see if you agree or have others to add):

  • There are a good number of risks related to supply chain and manufacturing concerns: getting raw materials, forecasting and scaling manufacturing appropriately, being able to get finished goods to customers.
    • Many of these risks were realized during the pandemic, and you can see this reflected in the numerous references to COVID-19 throughout the risk section.
    • Most of these risks would impact any business in this space to a large extent.
  • There are also a good number of risks around operating in the highly regulated healthcare space, which are shared with other players in the industry.
    • One particularly interesting note here is the privacy and security regulatory risk due to the acquisition of a diagnostics company, “a risk that has been elevated with the acquisition of Exosome Diagnostics, whose laboratory testing service is a healthcare provider that obtains and uses protected health information.”
    • i.e., they didn’t use to be directly in the diagnostics services business and now they are and it carries a different level of risk.
  • You can also tell that this business is fueled by innovation through references to risks around hiring and retaining highly skilled workers and protecting intellectual property.
    • Risks may not be uniformly shared across the healthcare sector, but these are fairly standard fare for the life sciences.
  • You can also see specific financial risks related to Bio-Techne, in particular around their Credit Agreement that bears interest at a variable rate and the fact that they are subject to risk from exchange rates due to their international presence.

Even if you’re familiar with a business, it’s worth going back through “Item 1. Business” and “Item 1A. Risk Factors” in its most recent annual report.

Start here, and you’ll have a foundation for the analytical work to come. Along the way, we’ll also dig into what some of the financial terms in the risk factors mean and how they impact the business. To keep up with this series, consider joining my mailing list to be updated when the next installment comes out.

Illustration of a scientist explaining business finance concepts

Why am I writing about finance?

Many scientists and engineers I’ve worked with have expressed frustration at not being able to have the kind of influence they want over the strategic directions of the companies in which they work. Oftentimes they feel their perspectives are being dismissed, particularly in discussions with colleagues in other functions.

But in the wise words of a mentor of mine, ‘if you want business people to listen to you, you have to be able to speak in a language they will understand.’ That language is, by and large, the language of finance. If you can frame the opportunities you see in language that your non-scientific colleagues can easily understand (and then explain to the board of directors), your ideas are much more likely to gain traction.

Similarly, scientific leaders will be better equipped to identify and prioritize scientific programs and investments if they can connect the dots between technical advancements and the ever-important bottom line (which, it turns out, refers to an actual line in the income statement!).

So my hope is that when armed with a little better financial intelligence, scientists and engineers can start to bridge the gap between the technical aspects of our business and the business end of the business.

Of course, I myself am one of these scientists. And so a big part of why I am writing this series is to force myself to dig deeper into some of the learnings I have gleaned from books, podcasts, and articles along the way (including frantically looking up terms like GAAP and EBIDTA during earnings calls and executive meetings). By virtue of my scientific background, hopefully the language I use throughout this series will be a little less opaque and a little more understandable for those of us who are more likely to be reading Nature articles than the Economist.

Specifically, in this mini-series, we will cover:

  • Some basics on financial statements
  • The big three financial statements (and their component parts):
    • the income statement
    • the balance sheet
    • the cash flow statement
  • Key ratios or evaluating the financial health of a business
  • Numbers investors care about and why
  • How to understand whether a new project/investment has (financial) merit through Net Present Value

To start, a couple references and an important acknowledgement. My initial foray into the wonderful world of finance was inspired by my friend Jeff Krimmel’s frequent LinkedIn posts on business and strategy in the energy sector. Jeff and I met as PhD students at Caltech, and I have been awed by his seamless transition from hardcore engineering to business and strategy, and am always impressed by his insightful discourse. I highly recommend checking out Jeff on LinkedIn and perusing his mini-course on Energy Finance. You’ll notice that this course closely mimics his course in places (with his blessing).

Another important source here is the book, Financial Intelligence. A Manager’s Guide to Knowing What the Numbers Really Mean, by Karen Berman and Joe Knight. It’s a great read and has many details that I won’t cover in this series.

In any case, I hope you enjoy! I would love to hear your questions, thoughts, and comments along the journey. And if you are really keen, join my mailing list so you don’t miss the future installments of this series.

Page 2 of 2

Powered by WordPress & Theme by Anders Norén